Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Pomalidomide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Pomalidomide as a study intervention. Browse Pomalidomide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 12:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
204
Shown on this page
12
Current sort
Recently updated
Therapy scope
Pomalidomide
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Pomalidomide. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 181–192 of 204 matching trials for Pomalidomide.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
No Longer Available No phase listed Expanded access

Expanded Access for CC-4047

NCT03723096
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CC-4047
Drug
Lead sponsor
Celgene
Industry
Eligibility
Not listed
U.S. locations
1
States / cities
Summit, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 23, 2026, 12:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect and CYP1A2 Induction Study in Healthy Subjects

NCT02168205
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Pomalidomide, Caffeine, Tobacco
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
40 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 23, 2026, 12:05 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

NCT01311687
View directory record Official record
Conditions
Multiple Myeloma
Interventions
pomalidomide, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 23, 2026, 12:05 AM EDT
Terminated Phase 1 Interventional

Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

NCT02462525
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ABBV-838, Pomalidomide, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
Chicago, Illinois • Ann Arbor, Michigan • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 23, 2026, 12:05 AM EDT
Completed Phase 2 Interventional Results available

Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide

NCT01794039
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Dexamethasone, Lenalidomide, Pomalidomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 23, 2026, 12:05 AM EDT
Withdrawn Phase 2 Interventional

An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma

NCT03227432
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Pomalidomide, Elotuzumab, Nivolumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 23, 2026, 12:05 AM EDT
Completed Phase 1 Interventional

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

NCT02071888
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Macroglobulinemia (WM), Other B-cell NHL Subtypes, Including WM, T-cell NHL
Interventions
CB-839, CB-839 and low dose dexamethasone, CB-839, pomalidomide, and low dose dexamethasone
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Scottsdale, Arizona • Denver, Colorado • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 23, 2026, 12:05 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma

NCT01979276
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Romidepsin, pomalidomide, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 23, 2026, 12:05 AM EDT
Completed Phase 2 Interventional Results available

CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis

NCT00558896
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
dexamethasone, pomalidomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 23, 2026, 12:05 AM EDT
Completed Phase 1 Interventional

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

NCT02103335
View directory record Official record
Conditions
Multiple Myeloma in Relapse, Refractory Multiple Myeloma, Multiple Myeloma
Interventions
pomalidomide, marizomib, low-dose dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2017 · Synced Oct 23, 2026, 12:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

NCT01432600
View directory record Official record
Conditions
Myeloma
Interventions
Pomalidomide, Dexamethasone, Cyclophosphamide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
San Francisco, California • Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 23, 2026, 12:05 AM EDT
Withdrawn Phase 2 Interventional

UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination

NCT02578121
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib, Pomalidomide, Dexamethasone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 23, 2026, 12:05 AM EDT

About this Pomalidomide clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Pomalidomide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Pomalidomide.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Pomalidomide.